3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Burkitt Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
trastuzumab deruxtecan
2
Cisplatin
2
Biopsy
2
pembrolizumab
1
luprolide acetate gel depot
1
entrectinib
1
dehydroftorafur
1
darolutamide
1
ceralasertib
1
apalutamide
1
amivantamab
1
Surveys and Questionnaires
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Platinum
1
Pemetrexed
1
Leuprolide
1
Immunoglobulin G
1
Gonadotropin-Releasing Hormone
1
Glutamate Carboxypeptidase II
1
Fluorouracil
1
Docetaxel
1
Disulfides
1
Carboplatin
1
Bevacizumab
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Dasatinib
×
30 days
×
Clear all
No trials found.